SCHEMBL5537563

SCHEMBL5537563

CCOc1ccccc1CN[C]=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.54
MAPT P10636 2/20 0.54
NPSR1 Q6W5P4 2/20 0.54
ALDH1A1 P00352 4/20 0.54
ATM Q13315 2/20 0.53
MEN1 O00255 2/20 0.53
GAA P10253 2/20 0.53
KMT2A Q03164 2/20 0.53
POLB P06746 2/20 0.53
THRB P10828 2/20 0.53
RECQL P46063 1/20 0.53
BLM P54132 1/20 0.53
PLEC Q15149 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
MAPK1 P28482 1/20 0.51
KDM4E B2RXH2 3/20 0.49
LMNA P02545 3/20 0.47
USP2 O75604 1/20 0.47
PKM P14618 1/20 0.47
ALOX15 P16050 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL513763 0.82 ALDH1A1 (0.58) MAPTALDH1A1MEN1GAAKMT2A
SCHEMBL9033719 0.80 MAPK1 (0.73) L3MBTL1MAPTNPSR1ALDH1A1ATM
SCHEMBL1254288 0.78 ALDH1A1 (0.60) L3MBTL1MAPTNPSR1ALDH1A1ATM
SCHEMBL5547134 0.78 TAS1R3 (0.45) L3MBTL1MAPTNPSR1ALDH1A1ATM
SCHEMBL5546693 0.77 GABRA1 (0.43) L3MBTL1MAPTNPSR1ALDH1A1GAA
SCHEMBL31054 0.77 L3MBTL1 (0.84) L3MBTL1MAPTNPSR1ALDH1A1ATM
SCHEMBL910695 0.77 L3MBTL1 (0.59) L3MBTL1MAPTNPSR1ALDH1A1ATM
SCHEMBL1521207 0.77 ALDH1A1 (0.63) L3MBTL1MAPTNPSR1ALDH1A1ATM
SCHEMBL15782766 0.77 ALDH1A1 (0.65) L3MBTL1MAPTNPSR1ALDH1A1ATM
SCHEMBL10282637 0.77 ALDH1A1 (0.68) L3MBTL1MAPTNPSR1ALDH1A1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 L3MBTL1 1931/4885MAPT 4117/4885NPSR1 747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.